Brokerages Set PDS Biotechnology Co. (NASDAQ:PDSB) Target Price at $14.25

Shares of PDS Biotechnology Co. (NASDAQ:PDSB) have earned a consensus recommendation of “Buy” from the five analysts that are presently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $14.25.

PDSB has been the subject of several recent analyst reports. Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research note on Thursday, August 1st. Finally, B. Riley cut their target price on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, June 12th.

Institutional Investors Weigh In On PDS Biotechnology

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in PDS Biotechnology by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after buying an additional 82,135 shares during the period. Inspirion Wealth Advisors LLC lifted its position in shares of PDS Biotechnology by 1.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock worth $1,054,000 after purchasing an additional 4,917 shares in the last quarter. Blair William & Co. IL lifted its position in shares of PDS Biotechnology by 204.4% during the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after purchasing an additional 81,743 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of PDS Biotechnology during the second quarter worth $146,000. Finally, Squarepoint Ops LLC acquired a new position in shares of PDS Biotechnology during the second quarter worth $120,000. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

PDS Biotechnology Trading Up 2.0 %

NASDAQ PDSB opened at $3.06 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84. The firm’s fifty day moving average price is $3.38 and its 200 day moving average price is $3.52. The company has a market capitalization of $112.24 million, a price-to-earnings ratio of -2.25 and a beta of 1.88. PDS Biotechnology has a 12 month low of $2.53 and a 12 month high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same quarter in the previous year, the company earned ($0.37) EPS. On average, sell-side analysts expect that PDS Biotechnology will post -1.3 earnings per share for the current fiscal year.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.